As the global regenerative medicine market continues to grow, Pharmgen Science is seeking to secure new growth drivers through this sector.
On June 9, Pharmgen Science announced that it has signed a memorandum of understanding (MOU) with TS Bio to expand its business into regenerative medicine and biopharmaceuticals.
This agreement is part of a strategic collaboration aimed at leveraging Pharmgen Science's capabilities in drug development, regulatory approval, and commercialization to broaden its business scope in regenerative medicine and biopharmaceuticals.
Founded in 2017, TS Bio is a biotechnology company specializing in research and development of cell therapies and gene therapies based on immune cells and stem cell technologies. The company operates a cell storage business utilizing facilities that meet Good Manufacturing Practice (GMP) standards and is actively engaged in regenerative medicine-related projects, enhancing its technical and business capabilities in the field.
The two companies plan to collaborate in various areas, including sharing information on clinical pipelines in regenerative medicine and biopharmaceuticals, joint research efforts, evaluating the feasibility of new drug development and clinical applications, and establishing strategies for commercialization, manufacturing, and distribution.
A representative from Pharmgen Science stated, "We will play a leading role in enhancing the practical commercialization potential of our development achievements based on our accumulated experience in regulatory approval and commercialization, thereby strengthening our competitiveness in the fields of regenerative medicine and biopharmaceuticals."
The regenerative medicine industry is experiencing rapid growth, with cell therapies and gene therapies serving as key growth drivers. Development of immune cell-based therapies is also progressing vigorously, with thousands of clinical trials reportedly underway globally, and the domestic regenerative medicine market is expanding as well.
A Pharmgen Science official remarked, "This agreement marks an important milestone in the company's mid-to-long-term growth strategy, and we aim to create new business opportunities through our expansion into regenerative medicine and biopharmaceuticals."
On June 9, Pharmgen Science announced that it has signed a memorandum of understanding (MOU) with TS Bio to expand its business into regenerative medicine and biopharmaceuticals.
This agreement is part of a strategic collaboration aimed at leveraging Pharmgen Science's capabilities in drug development, regulatory approval, and commercialization to broaden its business scope in regenerative medicine and biopharmaceuticals.
Founded in 2017, TS Bio is a biotechnology company specializing in research and development of cell therapies and gene therapies based on immune cells and stem cell technologies. The company operates a cell storage business utilizing facilities that meet Good Manufacturing Practice (GMP) standards and is actively engaged in regenerative medicine-related projects, enhancing its technical and business capabilities in the field.
The two companies plan to collaborate in various areas, including sharing information on clinical pipelines in regenerative medicine and biopharmaceuticals, joint research efforts, evaluating the feasibility of new drug development and clinical applications, and establishing strategies for commercialization, manufacturing, and distribution.
A representative from Pharmgen Science stated, "We will play a leading role in enhancing the practical commercialization potential of our development achievements based on our accumulated experience in regulatory approval and commercialization, thereby strengthening our competitiveness in the fields of regenerative medicine and biopharmaceuticals."
The regenerative medicine industry is experiencing rapid growth, with cell therapies and gene therapies serving as key growth drivers. Development of immune cell-based therapies is also progressing vigorously, with thousands of clinical trials reportedly underway globally, and the domestic regenerative medicine market is expanding as well.
A Pharmgen Science official remarked, "This agreement marks an important milestone in the company's mid-to-long-term growth strategy, and we aim to create new business opportunities through our expansion into regenerative medicine and biopharmaceuticals."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.